MAYO CLINIC LABORATORIES

1-800-533-1710

KRASW

KRAS Somatic Mutation Analysis, Peritoneal Fluid

Patient ID	Patient Name		Birth Date	Sex	Age
SA00151721	TESTING, KRASW		1977-02-01	F	45
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00151721	SA00151721	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		25 Mar 2022 07:00			

KRAS Mutation Analysis, Peritoneal

Result Summary

MCR

NEGATIVE

Result

MCR

KRAS status: Wild-type

Interpretation

MCR

The results of this assay should be interpreted in the context of other clinicopathologic findings. In the context of molecular peritoneal staging of pancreatic ductal adenocarcinoma during staging laparoscopy with peritoneal washings and cytology, the absence of detectable peritoneal fluid mutant cfKRAS (negative test) has been associated with clinically negative laparoscopic findings (no gross metastases and/or negative peritoneal cytology) and non-elevated peritoneal fluid CA19–9 and/or CEA, and may portend a decreased risk of residual/recurrent pancreatic cancer metastases within the peritoneal cavity. However, a negative result does not entirely rule out a residual/recurrent disease.

REFERENCES

1. J Am Coll Surg. 2021 Jul;233(1):73–80 (PMID 34022414)

Specimen

MCR

Peritoneal

Method

MCR

Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. Tumor DNA was isolated and evaluated for the presence of KRAS codons 12, 13, 61, and 146 mutations using digital droplet PCR analysis.

Disclaimer

[1] MCR

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

This assay was designed to detect KRAS codon 12, 13, 61, and 146 mutations.

A negative result does not rule out the presence of a mutation that may be present but below the limit of detection for this assay (approximately 0.1–0.5%).

Released By

MCR

Benjamin R. Kipp, Ph.D.

Received: 25 Mar 2022 09:33 **Reported:** 25 Mar 2022 13:58

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292